Cystic fibrosis (CF) is the most common fatal genetic disease affecting Canadian children and young adults, without a cure. Nanoparticles (NPs) have emerged as a promising strategy for delivering genetic treatments for various diseases. However, the development of NPs to treat CF has encountered many obstacles. This is mostly because the human airways, which constantly secrete mucous, pose a challenging environment for the efficient NP-mediated delivery of gene therapy. Several strategies have been proposed and tested; however, rational design criteria for these NPs are still missing.
Chronic obstructive pulmonary disease (COPD) is a 3rd leading cause of death (1) which decreases lung function due to irreversible airway obstruction. The main indicator of the progression of COPD is a rate of the forced expiratory volume of 1 second (FEV1) decline. The intern will build the prediction model for the slope of FEV1 decline and find the genetic variants that affect these FEV1 changes. Some variable selection machine learning algorithms will be applied to screen important genetic variants and the performance of prediction on FEV1 change will be compared.
To an unprecedented degree in the history of HIV/AIDS, people with HIV/AIDS (PLHIV) are aging largely owing to the success of treatment. As a relatively new phenomenon, research on HIV/AIDS and aging is only just emerging, and remains largely epidemiological in focus. One leading epidemiological study called COAST comes from the B.C. Centre for Excellence in HIV/AIDS, a world-renowned HIV/AIDS research organization. COAST assembles administrative epidemiological data to examine aging PLHIV health trends in B.C.
This study focuses on identifying best practices to guide the development of the PHC healthcare innovation and learning campus. PHC and the UBC research team seeks to build a design structure matrix (DSM) to inform the PHC about governance, key process, organizing structures, operating practices, intellectual property (IP), partnering approaches, partnership agreements, and implementation plans for developing an innovation hub ecosystem.
There are 2.6 million Canadians with Chronic Obstructive Pulmonary Disease (COPD). COPD is a disease characterized by progressive loss of lung function that leads to shortness of breath, poor quality of life, reduced productivity, emergency visits, hospitalizations and mortality. The World Health Organization estimates that COPD will be the 3rd leading cause of death worldwide by 2030, accounting for more than 7 million deaths/year and 11,000 deaths/year in Canada.
Chronic obstructive pulmonary disease (COPD) is an important global health problem afflicting 384 million people and causing 3 million deaths worldwide each year. Currently, there are no effective therapies for COPD patients. In this proposal, we are developing a novel technology that will both monitor the severity of disease in COPD patients, and allow researchers to better study potential targets and pathways for the design of new COPD drugs. Immune cells, such as neutrophils and macrophages, play important roles in the lungs of COPD patients.
Chronic Obstructive Pulmonary Disease (COPD) is a progressive, debilitating, chronic respiratory disease that affects 600 million people worldwide and is responsible for 3 million deaths worldwide each year. Given the recent advances in artificial intelligence (AI) and the availability of large datasets from both the public and private sectors, our project applies AI to analyze large-scale medical datasets and develops tools capable of performing accurate diagnosis, severity assessment, and prognosis of COPD.
Chronic Obstructive Pulmonary Disease (COPD) is a common illness that affects millions of Canadians, yet there are no effective therapies to treat it. Genes play a role in COPD development, and our proposal aims at identifying those genes in lung tissue that cause the disease. The Providence Airway Centre is very committed at helping COPD patients in Canada and worldwide. The proposed studies with Drs.
Chronic obstructive pulmonary disease (COPD) is an inflammatory disorder of the lung, and one that affects 2.6 million Canadians and 380 million people worldwide. Although the disease affects a large population worldwide the therapies used for treatment remain imprecise. With the lack of disease modifying therapies there is a pressing need to discover novel targets to promote new therapeutic discoveries and ultimately improve the care and health outcomes of patients with COPD.
Chronic Obstructive Pulmonary Diseases (COPD) is a lung disease that cause a lot of suffering to the Canadian population. To accelerate the drug discovery process, an old blood pressure lowering medication was tested to block the progression of COPD. A patient study showed that the old medication did provide some protective effect to the lung airways of COPD patients. However, we have found that this old medication does not slow down COPD by lowering blood pressure, but rather by acting on a new, unknown target.